Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide/dexamethasone (EPd) vs Pd for treatment of relapsed/refractory multiple myeloma (RRMM): results from the phase 2, randomized open-label ELOQUENT-3 study, EHA 2018, abstract LB2606.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie